SGLT2 inhibitors showed significantly improved mortality benefits compared with DPP-4 inhibitors in patients with diabetic kidney disease (DKD) in a large target trial emulation study that adds ...
Relative to GLP-1RA and DPP-4 inhibitor use, SGLT2 inhibitor use was associated with an increased risk for erythrocytosis but not an increased risk for thrombosis in T2D. Among individuals with type 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results